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Transcriptional Analysis of Vitiligo Skin Reveals the
Alteration of WNT Pathway: A Promising Target for
Repigmenting Vitiligo Patients
Claire Regazzetti1,6, Florence Joly2,6, Carine Marty2, Michel Rivier2, Bruno Mehul2, Pascale Reiniche2,
Carine Mounier2, Yves Rival2, David Piwnica2, Marine Cavalié3, Bérengère Chignon-Sicard4, Robert Ballotti5,
Johannes Voegel2 and Thierry Passeron1,3
Vitiligo affects 1% of the worldwide population. Halting disease progression and repigmenting the lesional skin
represent the two faces of therapeutic challenge in vitiligo. We performed transcriptome analysis on lesional,
perilesional, and non-depigmented skin from vitiligo patients and on matched skin from healthy subjects. We
found a signiﬁcant increase in CXCL10 in non-depigmented and perilesional vitiligo skin compared with levels in
healthy control skin; however, neither CXCL10 nor other immune factors were deregulated in depigmented
vitiligo skin. Interestingly, the WNT pathway, which is involved in melanocyte differentiation, was altered
speciﬁcally in vitiligo skin. We demonstrated that oxidative stress decreases WNT expression/activation in
keratinocytes and melanocytes. We developed an ex vivo skin model and conﬁrmed the decrease activation of
the WNT pathway in human skin subjected to oxidative stress. Finally, using pharmacological agents that activate
the WNT pathway, we treated ex vivo depigmented skin from vitiligo patients and successfully induced
differentiation of resident stem cells into pre-melanocytes. Our results shed light on the previously
unrecognized role of decreased WNT activation in the prevention of melanocyte differentiation in depigmented
vitiligo skin. Furthermore, these results support further clinical exploration of WNT agonists to repigment vitiligo
lesions.
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INTRODUCTION
Vitiligo is a disease of acquired depigmentation of the skin,
sometimes affecting hair follicles. This condition affects
0.5–1% of the world population. Previous studies have
clearly demonstrated that vitiligo greatly impairs the quality
of life of affected individuals, and, as such, the development
of an effective therapy is critical (Radtke et al., 2009;
Silverberg and Silverberg, 2013). The pathophysiology is
complex and involves many cellular players. Both oxidative
stress and the immune system have roles in vitiligo in
genetically predisposed individuals (Jin et al., 2012;
Passeron and Ortonne, 2012; Spritz, 2012; Bellei et al.,
2013; Schallreuter et al., 2013). One of the main challenges of
studying vitiligo is that the affected cells, the melanocytes, are
no longer present in the affected lesional skin. Animal models
using reactive T cells against melanocyte antigens have
provided interesting data about the immune reaction that is
thought to be involved in the depigmentation of vitiligo skin,
but these models are not adapted for studying the mecha-
nisms of melanocyte differentiation and repigmentation
in vitiligo skin (Mosenson et al., 2013; Rashighi et al.,
2014). Although currently available treatments can provide
cosmetically acceptable repigmentation (475%; Taieb et al.,
2013), repigmentation consisting of the differentiation and
proliferation of new melanocytes in depigmented vitiligo skin
remains difﬁcult to achieve in most cases.
In order to further characterize the pathophysiological
mechanisms involved in vitiligo, we performed transcriptome
(Affymetrix) analysis in combination with expression proﬁ-
ling of cytokines and chemokines in stratum corneum
from lesional, perilesional, and non-depigmented skin
samples from 10 vitiligo patients as well as from
localization-matched skin samples from 10 healthy volun-
teers. Functional analyses were then performed to further
explore our ﬁndings using in vitro experiments and an ex vivo
skin model of vitiligo.
See related commentary on pg 2921 ORIGINAL ARTICLE
1C3M, INSERM U1065, team 12, Nice, France; 2Galderma R&D, Sophia-
Antipolis, France; 3Department of Dermatology, University Hospital Center of
Nice, Nice, France; 4Department of Plastic Surgery, University Hospital Center
of Nice, Nice, France and 5C3M, INSERM U1065, team 1, Nice, France
Correspondence: Thierry Passeron, Department of Dermatology, Archet 2
hospital, University Hospital Center of Nice, 151, Route de St Antoine de
Ginestière, 06200, Nice, France. E-mail: passeron@unice.fr
6These authors contributed equally to this work.
Received 7 April 2015; revised 1 July 2015; accepted 19 July 2015; accepted
article preview online 31 August 2015; published online 24 September 2015
© 2015 The Society for Investigative Dermatology www.jidonline.org 3105
RESULTS
Transcriptome analysis revealed a low-level immune reaction in
non-depigmented and perilesional vitiligo skin and repression of
the WNT pathway in depigmented skin
A total of 118 genes were upregulated, and 138 were
downregulated in lesional vitiligo skin compared with the
skin from healthy controls (Figure 1a). When perilesional and
non-depigmented vitiligo skin samples were compared with
samples from healthy controls, 110 and 98 annotated genes
were found to be upregulated, and 21 and 18 annotated
genes were downregulated, respectively. Ingenuity pathway
analysis of overlapping canonical pathways revealed signiﬁcant
deregulation of melanocyte development and pigmentation
signaling, circadian signaling, and the WNT/β-catenin path-
way in vitiligo lesions compared with control skin (Figure 1b).
Hierarchical clustering of genes that were differentially
expressed between lesional and healthy skin from all samples
highlighted a transcriptional signature of melanocyte loss with
an almost complete extinction of the expression of melanocyte
markers in lesional samples (Figure 1c). Although we sought to
identify modulations of genes reported to be expressed in
various immune cell subsets, we observed very few variations
among the vitiligo samples, and none reached the level of
statistical signiﬁcance (Supplementary Table S1 online).
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Figure 1. Transcriptomic analysis of vitiligo patients highlights the disappearance of melanocytes and the involvement of the WNT signaling pathway in the
absence of immune system activation. (a) Histogram of differentially expressed genes between lesional and healthy samples depicts a similar number of
signiﬁcantly upregulated and downregulated genes. (b) Ingenuity-based canonical pathways that were enriched in vitiligo lesional skin. Genes highlighted in bold
are upregulated, and those in italics were downregulated. (c) Cluster analysis of the microarray data from healthy skin (HS), non-depigmented non-lesional skin
(NLS), perilesional skin (PLS), and lesional skin (LS) from vitiligo subjects. All probes signiﬁcantly modulated between HS and LS samples (|FC|⩾ 1.5 with a
FDRo0.05, n=333) were included in the cluster analysis, and the transcriptional signature corresponding to melanocyte loss was the focus. Gene symbol, probe
set number, fold change between LS and HS samples, and FDR-adjusted P-values of melanocytic genes are presented in the accompanying table. FDR, false
discovery rate.
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Interestingly, a transcriptional network linking WNT signal-
ing and melanogenesis pathways was observed using
ingenuity pathway analysis (Supplementary Figure S1c
online). Lesional vitiligo skin is characterized by down-
regulated expression of lymphoid enhancer binding factor 1
(LEF1), the key transducer of the WNT signaling pathway, and
of downstream effectors, such as cadherin 2 and cadherin 3
and INF regulatory factor 4 (IRF4). Lesional skin is also
characterized by upregulation of negative regulators of the
WNT signaling pathway, such as p53, which is involved in
signal transduction of WNT players; TLE4, a Groucho family
member; and ZBTB33/Kaiso, which is involved in the
transcriptional repression of WNT target genes. Furthermore,
the transcription factor LEF1 directly induces expression
of microphthalmia-associated transcription factor (MITF),
which accordingly is downregulated in vitiligo skin. IRF4
has recently been identiﬁed as a direct target of LEF1 and
MITF. At the functional level, IRF4 transactivates MITF
function by binding to shared melanocytic gene promotors
(Praetorius et al., 2013). Furthermore, LEF1 and β-catenin
regulate melanogenesis through SOX10 transcriptional
induction, which in turn regulates the expression of the
EDNRB, PCSK2, and PLP1 genes.
Our transcriptional analysis also revealed modulation of
the circadian pathway in the vitiligo samples. Because of
the known variation of these genes during the day, we
investigated whether these modulations were due to the time
of sampling or were linked directly to vitiligo pathogenesis.
We analyzed the expression of the key circadian genes
(ARNTL/BMAL1, CLOCK, PER1, and NR1D1) with respect to
the hour when the samples were taken. A strong correlation
was found between the hour of sampling and gene expres-
sion, indicating that modulation of expression of these
circadian genes was not linked to vitiligo pathology but
rather to sequential biopsy sampling at 1-h intervals
(Supplementary Figure S2a online). Following synchroniza-
tion of melanocytes, LEF1 expression was not correlated with
ARNTL expression (Supplementary Figure S2b online), and
this ﬁnding was conﬁrmed at the messenger RNA (mRNA)
level for several WNT members examined during the course
of the circadian cycle (data not shown).
The results of the transcriptional analysis were then
examined with quantitative real-time reverse-transcriptase–
PCR using Taqman Low Density Array (Life Technology,
Carlsbad, CA, USA). A marked decrease in expression of all
the melanocytic genes in vitiligo skin compared with that in
control skin conﬁrmed the loss of melanocytes in the affected
vitiligo skin (Figure 2a). Analysis of the expression of LEF1,
which serves as a key marker of the activation of the WNT
pathway, revealed that this factor was downregulated in
lesional vitiligo skin, in accord with the results of the
transcriptional analysis (Figure 2b). Finally, because CXCL10
has been implicated in a mouse model of vitiligo (Rashighi
et al., 2014), we also analyzed CXCL10 expression in our skin
samples using Taqman Low Density Array. We observed a
signiﬁcant increase in CXCL10 expression in perilesional
skin but also in non-depigmented skin of vitiligo patients
compared with healthy controls; however, the level of
expression of CXCL10 in depigmented vitiligo lesions was
not different than that in healthy skin (Figure 2c).
These results indicated insigniﬁcant modulation of genes
involved in the immune reaction, although CXCL10
was signiﬁcantly upregulated in perilesionaland in non-
depigmented skin of vitiligo patients. Thus, these ﬁndings
highlighted the absence of an immune reaction in lesional
skin devoid of melanocytes and interestingly revealed a
downregulation of the WNT/β-catenin pathway in lesional
vitiligo skin.
Analysis of stratum corneum cytokines shows no signiﬁcant
dysregulation in vitiligo skin
A total of 62 cytokines were examined in the stratum corneum
of subjects with vitiligo and healthy volunteers via tape
stripping. Twelve cytokines were detected and quantiﬁed with
concentrations ranging from 1 to 7,000 pgmg−1 of protein
(Supplementary Table S2 online). No signiﬁcant difference in
the cytokine proﬁles between pathological and non-
pathological samples was observed (Supplementary Table
S3 online). The concentration of CXCL10 protein in the
stratum corneum was compared with the mRNA expression
obtained from skin biopsies. Although CXCL10 was found to
be signiﬁcantly upregulated within the non-lesional and
perilesional vitiligo skin compared with healthy controls at
the mRNA level, no signiﬁcant modulation was observed
at the protein level in the stratum corneum between these
samples (Supplementary Table S4 online). These results
demonstrate that cytokines do not accumulate in the stratum
corneum of lesional skin and that the immune reaction in
vitiligo therefore occurs at a very low level and is no longer
detectable in depigmented skin regions.
Oxidative stress decreases WNT pathway activity in the skin
As the WNT pathway appeared to be affected in vitiligo skin,
we sought to determine the speciﬁc factor responsible for this
dysregulation. Oxidative stress has been reported to inhibit
the WNT/β-catenin pathway in kidney cells (Shin et al., 2004),
and other studies support a role for oxidative stress in vitiligo
(Bellei et al., 2013; Schallreuter et al., 2013). We, therefore,
examined the impact of oxidative stress on WNT/β-catenin
activation in an ex vivo skin model. H2O2 decreased the
expression of LEF1 and CDH3 and of most WNT family
members, whereas the level of β-catenin remained stable
(Figure 3a and Supplementary Figure S3c online). H2O2 also
decreased the expression of the LEF1 and WNT family
members in melanocyte and keratinocyte cultures (Figure 3b)
and the activity of the TCF/LEF promoter in melanocyte
culture (Figure 3c). In agreement to the results obtained with
the transcriptome analysis, after 8 days of treatment with
H2O2, LEF1 and CDH3 remained decreased in ex vivo skin,
whereas the WNT members tended to exhibit increased
expression (Figure 3d and Supplementary Figure S3d online).
Development of an ex vivo model to study vitiligo skin
The difﬁculty in studying vitiligo lies in the absence of a
model that mimics the in vivo conditions and also contains
stem cells that could be targeted to induce repigmentation.
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Thus, we developed an ex vivo skin model that is viable long
enough to induce the differentiation of melanocyte stem cells
in vitiligo skin. In clinical practice, vitiligo lesions usually
require months to achieve complete or almost complete
repigmentation; however, in the best cases, the onset of
pigmentation can sometimes be observed after 15 days of
treatment. We therefore examined the morphologic charac-
teristics of skin after treatment with the pigmentation inducer
forskolin after 15 days of ex vivo culture following abdomi-
noplasty skin surgery. At this time, the morphology of the skin
remained stable, compared with the initial conditions. We
noted only a ﬂattening of the dermal–epidermal junction, and
such ﬂattening may be owing to a difference of tension in the
skin (Figure 4a). The ability of the skin to respond to forskolin
was analyzed by quantitative PCR and immunoﬂuorescence
by studying the expression of the melanogenic genes MITF,
dopachrome tautomerase (DCT), and tyrosinase. In order to
assess the dose response of forskolin, the skin was stimulated
by forskolin systemically every other day. As expected, the
initial response induced upregulation of MITF mRNA
(Figure 4b) and protein (Figure 4c) after 11 days of stimulation.
This phenomenon was transient, although expression
remained high after 15 days at a low forskolin concentration
(Figure 4b). After 15 days, we observed a strong increase of
the melanogenic enzymes DCT and tyrosinase at both the
mRNA and protein levels (Figures 4b and c). Despite the
activation of the melanogenesis pathway, we did not detect
an increase in melanin contain in the cells (data not shown).
In conclusion, our model of ex vivo skin culture was viable
and functional for as many as 15 days in culture.
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Figure 2. Gene expression analysis of the key factors emphasized by the transcriptomic analysis. Gene expression was measured by quantitative real-time
reverse-transcriptase–PCR of (a) melanocytic genes, (b) LEF1, and (c) CXCL10 mRNA. Non-lesional skin (NLS), perilesional skin (PLS), and and lesional skin (LS)
sample groups were compared with the healthy skin (HS) group using a t-test linear model without pairing. Differences in gene expression were considered
signiﬁcant if both the |fold change| was ⩾1.8 and the FDR value waso0.05. The y axis displays the fold change in expression relative to the pool of healthy skin
samples. The data were normalized relative to expression of HPRT, ACTB, and GAPDH. The error bars display the SE of three replicates. *Po0.05; **Po0.01;
***Po0.001. The TLDA validation set encompassed genes related to terminal differentiation of melanocytes (PMEL, MLANA, TYRP1, and DCT), transcription
factors involved in melanogenesis (MITF, FOXD3, KIT, and NANOG), and adhesion molecules expressed in melanocytes (PLXNC1, PCDH11X, CDH2, and
L1CAM). CDH2, cadherin 2; DCT, dopachrome tautomerase; FDR, false discovery rate; mRNA, messenger RNA; LEF1, lymphoid enhancer binding factor 1;
MITF, microphthalmia-associated transcription factor; TLDA, Taqman Low Density Array; TYR, tyrosinase.
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Pharmacological WNT pathway activators induce increased
WNT pathway expression in ex vivo cultured vitiligo skin
The WNT pathway is involved in melanocyte differentiation
(Yamada et al., 2013; Fukunaga-Kalabis et al., 2015), and
we have demonstrated that this pathway is altered in vitiligo
skin. In order to induce the differentiation of melanocyte
stem cells, we pharmacologically activated the WNT pathway
in ex vivo vitiligo skin using the WNT agonist (SKL2001) and
the glycogen synthase kinase (GSK)3β inhibitors lithium
chloride (LiCl) and CHIR99021. We obtained biopsies from
nine vitiligo subjects from diverse body locations (three from
the elbow, two from the trunk, two from the leg, one from the
arm, and one from the axilla). We then treated the ex vivo
cultures for 14 days via systemic stimulation every other
day with these WNT activators. Evaluation of the activation
of the WNT pathway indicated that treatment with LiCl,
CHIR99021, or SKL2001 induced all WNT members and
LEF1 at the mRNA level after 14 days of stimulation (Figure 5a
and Supplementary Figure 4 online).
Ex vivo treatment of depigmented skin biopsies from vitiligo
patients with WNT activators induces the differentiation of
resident stem cells into pre-melanocytes
As we succeeded in upregulating the WNT pathway in the ex
vivo vitiligo skin biopsies, we analyzed the expression of
melanoblast markers following treatment. The mRNA levels
of early melanoblast markers, such as PAX3 and BRN2, were
upregulated in biopsies stimulated with CHIR99021,
SKL2001, and LiCl (Figures 5b and c). This result suggests
initiation of melanocyte differentiation. MITF levels were
increased only in the skin treated with SKL2001 (Figure 5d);
however, this expression was transient following stimulation,
suggesting that the time response is different for the different
treatments. The pre-melanocyte marker DCT was increased in
response to all treatments, but this effect was stronger in
response to LiCl (Figure 5e).
We next employed immunoﬂuorescence to study the co-
expression of DCT and PAX3 in order to investigate whether
these treatments lead to the differentiation of melanocyte stem
cells in pre-melanocytes in the skin. In vitiligo skin biopsies
cultured under control conditions, we observed no or few
isolated cells expressing PAX3 and DCT (Figure 5f). Following
stimulation with Wnt activators (Figures 5g–i), we found many
clusters of cells co-expressing the two markers in the hair
follicles and in the dermis, representing melanocytes under-
going differentiation. Taken together, these results showed
that targeting the deﬁcient WNT pathway of vitiligo skin using
WNT agonists or GSK3β inhibitors leads to the differentiation
of melanocyte stem cells into pre-melanocytes.
DISCUSSION
Our results emphasize the complexity of vitiligo pathophy-
siology. Although these ﬁndings partially support the role of
the immune system, and notably CXCL10, in depigmentation
of the skin in vitiligo patients, these data also indicate that
neither CXCL10 nor other immune factors are deregulated in
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Figure 3. Oxidative stress decreases WNT pathway activity in the skin. In whole skin in ex vivo culture, NHM and NHK were stimulated for 24 h (b), 2 days (a),
or 8 days (d) with 25–100 μM H2O2. After mRNA extraction, reverse transcription was performed, and the relative gene expression of LEF1, β-catenin, and CDH3
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Renillaluciferase expression. *Po0.05; **Po0.01, ***Po0.001. mRNA, messenger RNA; LEF1, lymphoid enhancer binding factor 1.
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already depigmented vitiligo skin. Recently, the role of
CXCL10 and the INF-γ pathway in a vitiligo mouse model
and in some human vitiligo skin samples was demonstrated
(Harris et al., 2012; Rashighi et al., 2014). Interestingly, the
samples analyzed were selected because of the presence of
an immune inﬁltrate. Our results, which show an increase
in CXCL10 expression in perilesional skin compared with
healthy control skin, are consistent with these data; however,
we also discovered that CXCL10 expression is signiﬁcantly
increased within unaffected skin of vitiligo patients as
compared with healthy control skin, suggesting that even
non-depigmented skin in vitiligo patients has low-level
immune activation that culminates in CXCL10 expression.
On the contrary, we did not observe any increase in the
CXCL10 expression in depigmented lesions that lack mela-
nocytes. CXCL10 upregulation in non-lesional and perile-
sional skin may indicate a constitutive level of secretion by
vitiligo skin cells upon stress signaling. Indeed, CXCL10 is
induced by a variety of innate stimuli that induce IFN-α/β as
well as the adaptive immune cell cytokine IFN-γ. CXCL10 is
best known for its role in leukocyte trafﬁcking, primarily
acting on CXCR3-expressing CD4+ Th1 cells, CD8+ T cells,
and natural killer cells. Therefore, we speculate that skin-
resident memory T cells and/or melanocytes themselves may
serve as the initial CXCL10 producers, ultimately inducing
the recruitment of CXCR3+ cells. Once melanocyte destruc-
tion is complete and the immune reaction is no longer active,
CXCL10 is no longer produced in the lesional areas.
Interestingly, we recently demonstrated in a prospective
randomized placebo-controlled study that 0.1% tacrolimus
ointment applied twice weekly signiﬁcantly lowers the
relapse rate of successfully repigmented vitiligo lesions
(Cavalie et al., 2014). The efﬁcacy of this maintenance
therapy strongly suggests that a low-level immune reaction
occurs in the pigmented skin of vitiligo patients. The only
other transcriptome analysis performed in vitiligo skin before
now failed to reveal potent activation of the immune system,
although in contrast to our ﬁndings, this previous study
pointed to activation of some factors involved in innate
immunity (in particular, on natural killer cells; Yu et al., 2012).
Although we ensured that the lesions were clinically active,
we cannot rule out the possibility that the samples in the
perilesional skin were devoid of immune inﬁltrate. This may
have prevented the detection of immune dysregulation (aside
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from CXCL10) and may also explain the fact that we did not
observe activation of natural killer cells as previously shown
by Yu et al. (2012).
Recently, the WNT/β-catenin pathway was found to have a
key role in UVB-induced melanocyte stem cell differentiation
(Yamada et al., 2013). Within the skin, the secretion of WNT
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mainly by keratinocytes and melanocytes contributes
to the differentiation of stem cells in melanocytes. Our
transcriptional analysis reveals an alteration of the WNT/β-
catenin pathway in vitiligo skin with a signiﬁcant decrease in
LEF/TCF expression that was conﬁrmed using quantitative
real-time reverse-transcriptase–PCR. As LEF1 is predominantly
expressed by melanocytes in the skin, we cannot exclude the
possibility that this decrease merely reﬂects the absence of
melanocytes; however, other WNT pathway genes that were
found to be differentially expressed in the transcriptome
analysis are similarly expressed in keratinocytes and melano-
cytes (e.g., CDH3, TLE4, and Kaiso; Supplementary Figure 5
online). In addition, our functional analyses further support
the impact of the decreased activation of the WNT pathway in
vitiligo as decreased expression of LEF1 and decreased
activity of the LEF1/TCF promoter were observed after
oxidative stress and differentiation of resident stem cells was
induced in pre-melanocytes following ex vivo stimulation
with WNT activators.
Our transcriptome analysis also demonstrated that adhe-
sion proteins, including cadherins, were also decreased in
vitiligo skin. The WNT pathway is known to regulate
E-cadherin expression, and interestingly, recent data showed
decreased expression of E-cadherin across melanocyte
membranes in vitiligo patients, leading to decreased adhe-
siveness of these cells to the basal layer under oxidative and
mechanical stress (Wagner et al., 2015). Many studies have
emphasized the role of oxidative stress in vitiligo (Maresca
et al., 1997; Bellei et al., 2013; Schallreuter et al., 2013).
Furthermore, a link between oxidative stress and activation of
the immune response has recently been uncovered (Passeron
and Ortonne, 2012; Toosi et al., 2012), and our data clearly
indicate that oxidative stress decreases WNT pathway activity
in melanocytes and keratinocytes. WNT ligands and LEF1 are
ﬁrst decreased in both melanocytes and keratinocytes; yet,
decreased levels of LEF1 and CDH3 persist in vitiligo skin
ex vivo despite the augmentation of WNT probably owing to
compensation of the impaired pathway. In vitiligo lesions
devoid of melanocytes, the keratinocytes are presumably
responsible for the production of WNT proteins. Taking
into account the central role of the WNT/β-catenin path-
way on the differentiation of melanocyte stem cells, we
hypothesize that oxidative stress negative impacts the
differentiation of melanocytes in vitiligo skin. We, therefore,
directly addressed the defective differentiation of melanocyte
stem cells by stimulating the WNT/β-catenin pathway, which
was altered in vitiligo lesions. Using our ex vivo model for
depigmented skin of vitiligo patients, we demonstrated that
treatment with WNT agonists or GSK3β inhibitors induce
increased expression of melanocyte markers, triggering the
differentiation of resident melanocyte stem cells in pre-
melanocytes expressing PAX3 and DCT. Interestingly, we
observed pre-melanocytes not only in the hair follicles but
also in the dermis, suggesting that this approach may be
helpful for the differentiation of dermal stem cells of glabrous
skin (Li et al., 2010). The cells that expressed DCT and
PAX3 remained in the dermis, and we did not detect the
differentiated melanocyte marker tyrosinase at either the
mRNA or protein level (using immunohistochemistry) in these
cells (data not shown). Such localization and expression
patterns of melanocyte markers strongly suggest that these
cells are pre-melanocytes. In all likelihood, however, the
limited timeframe of our ex vivo model is too short to obtain
fully differentiated melanocytes.
Taken together, our results demonstrate that the immune
reaction in vitiligo occurs only at very low levels. Speciﬁcally,
an increase in CXCL10 expression in non-depigmented and
perilesional skin was observed, and an immune reaction is
no longer detectable in vitiligo lesions already devoid of
melanocytes. These ﬁndings also highlight a previously
unrecognized defect in WNT/β-catenin activation triggered
by oxidative stress, and this defect may effectively prevent the
differentiation of melanocyte stem cells (Figure 6). These
results not only provide a better understanding of the complex
pathophysiology of vitiligo but also support further clinical
exploration of WNT activators for repigmenting vitiligo
lesions.
MATERIALS AND METHODS
Patients for transcriptomic analysis
Ten patients with active non-segmental vitiligo, which is deﬁned by
the occurrence or the worsening of depigmented lesions in the past
3 months and having hypochromic borders upon Wood’s lamp
examination, were enrolled in the study after informed, written
consent was obtained. The study was approved by the local ethics
committee (N12.034). A 4-mm-skin biopsy was taken from each
patient in the center of a vitiligo patch, in the perilesional area
(deﬁned as 5mm outside of the lesion border), and in non-lesional
skin located in the same area but at least 3 cm from a depigmented
lesion. A 4-mm biopsy was also taken from 10 healthy patients and
served as a control that was matched for gender, age, and location.
The procedure for taking samples and the characteristics of the
patient population are described in Supplementary Figures S1a and
S1b online.
Transcriptomic analysis
Biopsies for the microarray analysis were stored in RNA Stabilization
Reagent (Qiagen, Venlo, The Netherlands) until use. For RNA
extraction, the samples were homogenized with a potter in Qiagen
lysis buffer (Qiagen). Total RNA was extracted using RNeasy
extraction kits (Qiagen) according to the manufacturer's protocol.
RNA quantity was measured using a Nanodrop Spectrophotometer
ND8000 (Thermo Fisher Scientiﬁc, Waltham, MA, USA). RNA
quality was monitored using a 2100 Bioanalyzer (Agilent
Technologies, Waldbronn, Germany). Probes were synthesized and
then hybridized on Affymetrix U133 Plus 2.0 chips (Affymetrix,
Santa Clara, CA, USA). All chips were normalized using the robust
multi-array average method (Bolstad et al., 2003). Only Affymetrix
identiﬁers (IDs) with expression ⩾ 2exp6(64) for at least 7 out of 10
samples in at least 1 sample group (lesional (LS), non-lesional (NLS),
perilesional (PLS), or healthy) were selected. Finally, 29,906 of
54,675 IDs that were initially present were kept for statistical
analyses, and thresholds of modulation of 1.5 and of − 1.5 were
selected for further analyses. Data analysis was performed on Array
Studio software (OmicSoft, Cary, NC, USA). A two-sided paired
Student’s t-test was performed. The Benjamini-Hochberg procedure
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(1995) was used for correction of multiple testing. The raw data are
available at NCBI GEO, accession number GSE65127.
Functional analysis of gene expression results
Average-linkage hierarchical clustering using Pearson correlation
was performed using the Cluster v.3.0 program (Eisen et al., 1998).
Graphic outputs were generated with the JavaTreeView3.0 software
(Saldanha, 2004). Functional annotation and gene networks for the
differentially expressed genes among sample groups were generated
using the QIAGEN IPA (QIAGEN, Redwood City, CA, USA; www.
qiagen.com/ingenuity).
Ex vivo skin culture
Skin from abdominoplasty surgery was used for the development of
the ex vivo skin culture model. The subcutaneous fat was removed,
and biopsies of 6 mm were taken from skin composed of dermis and
epidermis. For vitiligo skin biopsies, after informed consent was
obtained and the absence of melanocytes with Wood’s lamp was
veriﬁed, two to three 6-mm biopsies composed of dermis and
epidermis were taken from lesional skin (n= 9). The biopsies are
rapidly placed into a 0.4-μm Transwell chamber (Becton Dickinson,
Franklin Lakes, NJ, USA) and maintained under semi-liquid culture
conditions in “Skin long-term culture medium” (Biopredic, Saint
Grégoire, France). The skin was maintained at 37 °C in a 5% CO2
atmosphere. The culture medium that was supplemented with
forskolin (Sigma-Aldrich, Saint-Louis, MO), LiCl (Sigma-Aldrich),
CHIR99021 (Calbiochem, San Diego, CA, USA), or SKL2001 (Calbio-
chem) was changed every day during the 14-day period.
The methods for Luminex 200 system (Luminex Corporation,
Austin, TX) quantitation of cytokines in stratum corneum, cells,
quantitative real-time reverse-transcriptase–PCR, and histological
analyses are detailed in the Supplementary Methods online.
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